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Abstract We compared the inhibitory e¡ect of various cyclo-
dextrins (CyDs) on P-glycoprotein (P-gp) and multidrug resis-
tance-associated protein 2 (MRP2) function and examined the
contribution of cholesterol to the inhibitory e¡ect of 2,6-di-O-
methyl-L-cyclodextrin (DM-L-CyD) on the e¥ux activity of the
function in Caco-2 cell monolayers. Of various CyDs, DM-L-
CyD signi¢cantly impaired the e¥ux activity of P-gp and
MRP2. DM-L-CyD released P-gp and MRP2 from the mono-
layers in the apical side’s transport bu¡er and decreased the
extent of cholesterol as well as P-gp and MRP2 in caveolae
of Caco-2 cell monolayers, but not caveolin and £otillin-1. On
the other hand, DM-L-CyD did not change MDR1 and MRP2
mRNA levels. Therefore, these results suggest that the inhibi-
tory e¡ect of DM-L-CyD on P-gp and MRP2 function, at least
in part, could be attributed to the release of these transporters
from the apical membranes into the medium as secondary e¡ects
through cholesterol-depletion in caveolae after treatment of
Caco-2 cell monolayers with DM-L-CyD.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Intestinal P-glycoprotein (P-gp) and multidrug resistance-
associated protein 2 (MRP2) are ATP-dependent multidrug
e¥ux pumps, which can serve as active secretion systems or
absorption barriers by transporting drugs from the apical
membrane of intestinal cells into the lumen [1,2]. The sub-
strates transported by P-gp and MRP2 include a variety of
structurally and pharmacologically unrelated compounds such
as some anticancer agents, steroidal hormones, calcium chan-
nel blockers, immunosuppressive agents and L-blockers [3^6].
Cyclodextrins (CyDs) are host molecules which form inclu-
sion complexes with lipophilic drugs as guests and thus have
been utilized for improving their water solubility and dissolu-
tion rates [7]. Recently, several hydrophilic CyD derivatives
have been used, e.g. methylated, 2-hydroxypropylated, sulfo-
butylether and branched CyD derivatives [8^11]. In the cell
biology ¢eld, methyl-L-cyclodextrin (M-L-CyD) and 2-hy-
droxypropyl-L-CyD (HP-L-CyD), which are introduced the
substitution groups randomly, have been widely used as cho-
lesterol-depletion agents [12].
We recently demonstrated that 2,6-di-O-methyl-L-cyclodex-
trin (DM-L-CyD) signi¢cantly increased the low aqueous sol-
ubility and oral bioavailability of tacrolimus, an immuno-
suppressive agent, in rats and the improvement in oral
bioavailability was due not only to its solubilizing e¡ect but
also, at least in part, to its inhibitory e¡ect on the P-gp-medi-
ated e¥ux of tacrolimus from intestinal epithelial cells [13].
P-gp is reported to be localized in caveolae, £ask-shaped in-
vaginations, in which cholesterol and glycosphingolipids are
abundant in multidrug-resistant (MDR) cells and in brain
capillaries [14,15]. In addition, caveolae containing caveolin-
1 reside in the small intestinal brush border membranes [16].
Then, we postulated that DM-L-CyD may interact with cho-
lesterol in plasma membranes of enterocytes, resulting in
changes of caveolae function, which may eventually impair
the e¥ux activity of P-gp and MRP2 in enterocytes if these
transporters reside in caveolae. To clarify the hypothesis in
the present study, therefore, we studied the inhibitory e¡ects
of hydrophilic CyD derivatives on P-gp and MRP2 e¥ux
activity in Caco-2 cell monolayers and the e¡ect of DM-L-
CyD on the extent of P-gp, MRP2 and cholesterol in caveolae
of apical membranes and their release from the monolayers
into the apical side’s transport bu¡er.
2. Materials and methods
2.1. CyDs
2-Hydroxypropyl-K-cyclodextrin (HP-K-CyD), HP-L-CyD and
2-hydroxypropyl-Q-cyclodextrin (HP-Q-CyD) with an average degree
of substitution (DS) of the hydroxypropyl group of 4.0, 4.8 and 4.8,
respectively, as well as DM-L-CyD (DS=14) were obtained from
Nihon Shokuhin Kako. Sulfobutylether L-CyDs (SBE4- and SBE7-
L-CyDs, DS=3.9 and 6.2, respectively) were supplied by CyDex.
M-L-CyD (DS=10.5^14.7) was purchased from Sigma Chemicals.
2.2. Cytotoxicity and transepithelial electrical resistance (TEER)
Caco-2 cells (passages 40 and 60) were obtained from the American
Type Culture Collection and cultivated as reported previously [13].
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The e¡ects of CyDs on viability and integrity of Caco-2 cell mono-
layers were measured as reported previously [17]. In brief, intestinal
mitochondrial enzymatic activity was assayed using a Cell Counting
Kit (WST-1 method) from Wako Pure Chemical Industries. All TEER
values of Caco-2 cell monolayers grown on Transwell0 (6-well) were
measured by using Millicel0-ERS Voltmeter (Millipore). The TEER
value of Caco-2 cell monolayers was 761.4P 5.1 6/cm2.
2.3. Transport studies
The e¡ects of treating with CyDs on the transport of [3H]mannitol
(speci¢c activity, 19.7 Ci/Wmol, New England Nuclear) and the e¡ects
of pretreatment with CyDs on the rhodamine 123 (Molecular Probes)
and BCECF (2P,7P-bis(2-carboxyethyl)-5(6)-carboxy£uorescein; Mo-
lecular Probes) across Caco-2 cell monolayers were studied as de-
scribed previously [13]. Brie£y, [3H]mannitol was added to the apical
side’s transport bu¡er in the absence and presence of CyDs and in-
cubated for 60 min. On the other hand, the apical membranes were
pretreated with 10 mM CyDs for 30 min for the transport studies of
rhodamine 123 and BCECF. After washing the apical membranes,
rhodamine 123 (5 WM) or 2P,7P-bis(2-carboxyethyl)-5(6)-carboxy£uo-
rescein acetoxymethylester (BCECF-AM; 5 WM) was added to the
apical or basolateral side’s transport bu¡er. For other inhibitors,
the e¥ux of rhodamine 123 or BCECF was determined in the pres-
ence of 5 WM cyclosporin A or 200 WM indomethacin in the apical
and basolateral side’s transport bu¡ers without pretreatment. The
radioactivity of [3H]mannitol was counted in an Aloka LSC-3500
liquid scintillation counter. The concentrations of rhodamine 123
and BCECF in the transport bu¡er were determined by a high per-
formance liquid chromatography (HPLC) and a Hitachi F-4500 £uo-
rophotometer (excitation and £uorescence wavelengths were 439 nm
and 525 nm, respectively), respectively. The HPLC conditions were
the same as that reported previously [13]. The apparent permeability
coe⁄cient (Papp) was calculated using the following equation:
Papp ¼ ðdQ=dtÞ=ðAWC0Þ
where dQ/dt is the £ux across the monolayer (mol/s), A is the surface
area of the membrane (cm2), and C0 is the initial drug concentration
(mol/ml).
2.4. Release of membrane components
Caco-2 cells in 35 mm dishes were cultured in growth medium for
15 days before use. Prior to experiments, Caco-2 cell monolayers were
incubated for 24 h in growth medium supplemented with 10% FCS
containing [3H]cholesterol (5 WCi/ml, Amersham-Pharmacia Biotech).
The cell monolayers were washed three times with transport bu¡er
and incubated in transport bu¡er containing CyDs for 30 min. The
concentrations of [3H]cholesterol and total proteins in the transport
bu¡er were determined with an Aloka LSC-3500 liquid scintillation
counter and bicinchoninic acid reagent from Pierce Chemical with
bovine serum albumin as a standard, respectively. In some experi-
ments, 10 mM DM-L-CyD-containing transport bu¡er preloaded
with 1.6 mM cholesterol by incubation with free cholesterol for
7 days was used.
2.5. Western blotting
The expressions of P-gp, MRP2, caveolin and £otillin-1 were de-
tected by Western blotting. In brief, the samples were separated by
7%, 10% and 15% sodium dodecyl sulfate (SDS)-PAGE for the assay
of P-gp and MRP2, £otillin-1 and caveolin, respectively, and then
transferred onto PVDF membranes (NEN Life Science Products).
The membranes were blocked with 5% skim milk, and then probed
with C219 anti-human P-gp (Signet Laboratories), M2I-4 anti-MRP2
monoclonal antibody (Alexis Biochemicals), C13630 anti-caveolin
polyclonal antibody (BD Transduction Laboratories) or Clone 18
anti-£otillin-1 mouse IgG1 antibody (BD Transduction Laboratories).
After a wash, the membranes were incubated with peroxidase-conju-
gated secondary antibody and then the speci¢c protein bands were
detected using the ECL Western blotting analysis kit (Amersham-
Pharmacia Biotech). The bands were detected using the Lumino-im-
age analyzer LAS-1000 plus (Fuji¢lm).
2.6. Semiquantitative reverse transcription polymerase reaction
(RT-PCR)
The apical membranes of Caco-2 cell monolayers were treated with
CyDs for 30 min. Then, the membranes were scraped o¡ and the cells
were lysed. Total RNA was extracted from the lysates using a RNeasy
Mini Kit (Qiagen). Next, the samples were treated with deoxyribonu-
clease (1 U) and ribonuclease inhibitors (35 U) and complementary
DNA was synthesized by reverse transcription using the speci¢c re-
verse primers against human MDR1, MRP2 or L-actin gene and re-
verse transcriptase (SuperScript II). Then, PCR was conducted using
the speci¢c forward primers against the human MDR1, MRP2 and
L-actin genes. PCR was performed for 25 cycles of denaturation at
94‡C for 60 s, annealing at 55‡C for 60 s, and extension at 72‡C for
120 s. The ampli¢ed products were analyzed on 2% low melting tem-
perature agarose gels containing 0.1 Wg/ml of ethidium bromide.
2.7. Caveolae isolation
Low-density caveolae-enriched domains were isolated by a carbon-
ate-based fractionation method as described previously [18]. In brief,
Caco-2 cell monolayers cultured in 150 mm dishes were scraped into
2 ml of 0.5 M sodium carbonate (pH 11) and homogenized extensively
using a Potter-Elvehjem type homogenizer, Polytron tissue grinder
and a sonicator. The resulting homogenate was brought to 45% su-
crose by the addition of 2 ml of 90% sucrose in MES-bu¡ered saline
(MBS; 25 mM MES and 150 mM NaCl, pH 6.5) and overlaid with
two layers of 35% and 5% sucrose in MBS containing 0.25 M car-
bonate (4 ml each). The gradient was then centrifuged at 200 000Ug
for 18 h using a Beckman SW41Ti rotor. For the analysis of the
resulting gradient, 12 fractions (each 1 ml) were collected from the
top to the bottom of the gradient. 10 Wl of each fraction were sub-
jected to SDS^PAGE for the detection of P-gp, MRP2 and caveolin,
respectively. On the other hand, the cholesterol mass of each fraction
obtained from the sucrose gradient was determined using a Choles-
terol Kit Wako0 (Wako Pure Chemical Industries).
3. Results
3.1. Cytotoxicity and monolayer’s integrity
Fig. 1 shows the e¡ects of CyDs on viability of Caco-2 cells.
Tween 20, a non-ionic surfactant, was employed as a positive
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Fig. 1. Cytotoxicity of CyDs and Tween 20 in Caco-2 cells in
Hanks’ balanced salt solution (HBSS; pH 7.4) at 37‡C. (Closed
circles), DM-L-CyD; (open triangles), M-L-CyD; (closed triangles),
HP-K-CyD; (open squares), HP-L-CyD; (closed squares), HP-Q-
CyD; (open diamonds), SBE4-L-CyD; (closed diamonds), SBE7-L-
CyD; (closed inverted triangles), Tween 20. Cells were washed three
times with HBSS (pH 7.4) and then incubated for 60 min with 100
Wl of HBSS containing CyDs and Tween 20 at various concentra-
tions at 37‡C. After three washes with HBSS to remove CyDs and
Tween 20 again, cell viability was assayed by the WST-1 method.
Each point represents the meanPS.E.M. of six experiments.
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control and eventually provided almost complete cytotoxicity
even at 8.9 mM. HP-K-CyD, HP-L-CyD, HP-Q-CyD, SBE4-L-
CyD and SBE7-L-CyD were not cytotoxic to Caco-2 cells up
to 100 mM. On the other hand, DM-L-CyD and M-L-CyD
markedly reduced the viability of these cells above 50 mM and
100 mM, respectively. Next, we evaluated the integrity of tight
junctions of the monolayers as a molecular barrier, and the
e¡ects of CyDs on the TEER and the ability of mannitol to
permeate the monolayers were studied. As shown in Table 1,
100 mM HP-K-, HP-L-, HP-Q-, SBE4-L- and SBE7-L-CyDs as
well as 10 mM and 15 mM DM-L-CyD and 15 mM M-L-CyD
did not lower the TEER value, while 50 mM M-L-CyD did.
In addition, both DM-L-CyD and M-L-CyD changed the Papp
values of [3H]mannitol, a paracellular transport marker, only
very slightly at a concentration of 15 mM, but 50 mM M-L-
CyD signi¢cantly increased the values (Table 1). On the other
hand, 100 mM HP-K-, HP-L- and HP-Q-CyDs and sulfobuty-
lether L-cyclodextrins did not markedly increase the values
(Table 1). Taken together, these results suggest that M-L-
CyD and DM-L-CyD, particularly DM-L-CyD, strongly in-
teract with Caco-2 cell monolayers, resulting in a decline in
the monolayer’s integrity at higher concentrations.
3.2. DM-L-CyD, but not M-L-CyD, inhibits P-gp and
MRP2 function
To elucidate whether CyDs inhibit the P-gp- and MRP2-
mediated e¥ux of substrates from Caco-2 cell monolayers, the
e¡ects of various CyDs on basolateral to apical (BL-to-AP)
and apical to basolateral (AP-to-BL) transports of rhodamine
123 and BCECF, representative P-gp and MRP2 substrates,
respectively, were examined. The results were compared with
those for cyclosporin A and indomethacin, typical P-gp and
MRP inhibitors, respectively. Here the monolayers were pre-
treated with 10 mM CyDs for 30 min to avoid direct inter-
action between the substrates and CyDs as well as the cellular
damage, whereas they were treated with the inhibitors in the
presence of the substrates. In addition, it is also noteworthy
that CyDs provided neither cytotoxicity nor non-speci¢c para-
cellular transport at concentrations up to 10 mM during 30
min of incubation (Fig. 1 and Table 1). As shown in Fig.
2A,B, it is apparent that cyclosporin A markedly decreased
Table 1
E¡ects of CyDs treatment on TEER and permeation of [3H]mannitol (50 nM) through Caco-2 cell monolayers
System Caco-2
TEER % of initial value PappaU107 (cm/s)
control 116.7P 2.3 2.22P1.7
with DM-L-CyD (10 mM) 107.6P 1.5 2.33P0.4
with DM-L-CyD (15 mM) 103.2P 1.5 2.35P0.2
with M-L-CyD (15 mM) 104.5P 0.2 1.63P0.3
with M-L-CyD (50 mM) 83.3P 1.4* 2.60P0.4
with HP-K-CyD (100 mM) 120.0P 1.2 2.02P0.6
with HP-L-CyD (100 mM) 126.4P 0.3 1.81P0.0
with HP-Q-CyD 146.4P 1.5* 1.43P0.2
with SBE4-L-CyD (100 mM) 113.8P 1.8 2.87P0.3
with SBE7-L-CyD (100 mM) 92.4P 1.3* 2.31P0.6
*P6 0.05 versus control.
aPapp of AP-to-BL [3H]mannitol permeation.
6
Fig. 2. Inhibitory e¡ects of various agents on BL-to-AP (A,C) and
AP-to-BL (B,D) permeation of rhodamine 123 (A,B) and BCECF
(C,D) through Caco-2 cell monolayers. The apical membranes of
Caco-2 cell monolayers were pretreated with CyDs at 10 mM for 30
min at 37‡C. After a wash of the apical membranes, rhodamine 123
(5 WM) or BCECF-AM (5 WM) was added to the basolateral or api-
cal side’s transport bu¡er. For other inhibitors, the e¥uxes of rho-
damine 123 and BCECF were determined in the presence of 5 WM
cyclosporin A and 200 WM indomethacin in the apical and basolat-
eral sides’ transport bu¡ers without pretreatment. The concentra-
tions of rhodamine 123 and BCECF were determined by a HPLC
and a £uorescence spectrophotometer. Each value represents the
meanPS.E.M. of three experiments. *P6 0.05 versus rhodamine 123
or BCECF alone.
FEBS 26974 5-2-03
K. Yunomae et al./FEBS Letters 536 (2003) 225^231 227
the BL-to-AP permeation in the monolayers, but increased the
AP-to-BL permeation of rhodamine 123 only very slightly,
although the reason for no change in AP-to-BL permeation
remains unknown. Of CyDs, DM-L-CyD inhibited the BL-to-
AP transport by one-¢fth and augmented the AP-to-BL trans-
port of rhodamine 123 approximately 2.5-fold, compared to
the control. The pretreatments with other CyDs had much less
e¡ect on the permeation of rhodamine 123.
Fig. 2C,D show the e¡ects of CyDs on MRP2 function in
Caco-2 cell monolayers. Here BCECF-AM, a lipophilic deriv-
ative of BCECF was used. In the monolayers, BL-to-AP e¥ux
and AP-to-BL in£ux were inhibited and promoted by pre-
treatment with DM-L-CyD, respectively, although the inhibi-
tory e¡ect of DM-L-CyD on the BL-to-AP e¥ux was mark-
edly lower than that of indomethacin. Other CyDs changed
the e¥ux and in£ux of BCECF only very slightly. On the
Fig. 3. E¡ects of CyDs on the release of [3H]cholesterol (A) and total proteins (B) from Caco-2 cell monolayers. 100% represents total amounts
of [3H]cholesterol labeled in Caco-2 cell monolayers. Each value represents the meanPS.E.M. of 3^11 experiments. *P6 0.05 versus control
(without CyDs). C: Immunoblotting of P-gp and MRP2 released in the apical side’s transport bu¡er of Caco-2 cell monolayers. D: Immuno-
blotting of P-gp and MRP2 in Caco-2 cell monolayers. The monolayers were treated with 10 mM CyDs for 30 min at 37‡C and then total pro-
teins and P-gp, MRP2 levels in the apical side’s transport bu¡er and Caco-2 cell monolayers were assayed by the bicinchoninic acid reagent
and immunoblotting, respectively. E: MDR1 and MRP2 mRNA levels in Caco-2 cell monolayers. The monolayers were treated with 10 mM
CyDs for 30 min at 37‡C and then MDR1 and MRP2 mRNA levels in the cells were assayed by RT-PCR. F: E¡ects of an addition of choles-
terol to DM-L-CyD-containing apical side’s transport bu¡er on the release of P-gp and MRP2 in the bu¡er of Caco-2 cell monolayers.
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Fig. 4. A: Localization of cholesterol in caveolae of Caco-2 cell monolayers. The amount of cholesterol in each fraction after sucrose gradient
centrifugation was determined with a Cholesterol Kit Wako0. (Open circles), control; (closed circles), DM-L-CyD. B: E¡ect of DM-L-CyD on
the extent of cholesterol in caveolae fraction of Caco-2 cell monolayers. Bars refer to percent permeation as compared with control which was
arbitrarily de¢ned as 100%. Fractions 4^6 were de¢ned as caveolae fraction. Each value represents the meanPS.E.M. of three experiments.
C: E¡ect of DM-L-CyD on P-gp and MRP2 localization in caveolae and non-caveolae fractions in Caco-2 cell monolayers. The monolayers
were treated with 10 mM DM-L-CyD for 30 min at 37‡C, caveolae were isolated, and the P-gp, MRP2, caveolin and £otillin-1 expressions
were assayed by immunoblotting.
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other hand, the impairment of AP-to-BL transport of BCECF
following the treatment with indomethacin might be attrib-
uted to the inhibitory e¡ect on MRP3, which resides in baso-
lateral membranes of Caco-2 cell monolayers. These results
indicate that of all the CyDs used here DM-L-CyD signi¢-
cantly inhibit the P-gp- and MRP2-mediated e¥ux from
Caco-2 cell monolayers.
3.3. DM-L-CyD releases cholesterol as well as P-gp and MRP2
from Caco-2 cell monolayers
It is well recognized that L-CyDs release biological mem-
brane components such as cholesterol and phospholipids from
erythrocytes and nasal epithelium cells, resulting in release of
proteins from cell membranes [19,20]. First we examined
whether CyDs release cholesterol from the apical membranes
of the monolayers. The treatment with DM-L-CyD and M-L-
CyD raised the cholesterol level released from the monolayers
(Fig. 3A), consistent with the results reported by Ohtani et al.
who examined the release of lipids from erythrocytes [19].
Indeed DM-L-CyD increased the release of [3H]cholesterol
approximately 30-fold and 1.4-fold, compared with negative
control and M-L-CyD, respectively (Fig. 3A). These results
imply that DM-L-CyD attenuates P-gp and MRP2 function
through cholesterol depletion, at least in part, in the apical
membranes.
To gain an insight into the mechanism for the inhibitory
e¡ect of DM-L-CyD on P-gp and MRP2 function, we exam-
ined whether P-gp and MRP2 are released from the mono-
layers into the apical side’s transport bu¡er. At ¢rst, we com-
pared the treatment e¡ects of CyDs (10 mM) for 30 min on
the release of total proteins from the apical membranes of
Caco-2 cell monolayers. As shown in Fig. 3B, the greatest
e¡ect on the release of total proteins was shown by DM-L-
CyD, i.e. DM-L-CyD, M-L-CyD and HP-L-CyD released to-
tal proteins approximately 1.8, 1.5 and 1.3-fold higher than
the negative control, respectively. It is important to note that
the bands corresponding to P-gp and MRP2 were clearly ob-
served in the apical side’s transport bu¡er after treatment with
10 mM DM-L-CyD, compared to that with M-L-CyD and
HP-L-CyD (Fig. 3C), but the bands corresponding to caveolin
and £otillin-1, marker proteins of caveolae, were not observed
(data not shown), indicating that the presence of the trans-
porters in the bu¡er is not due to the contamination of cells
removed from culture dishes. In addition, DM-L-CyD re-
duced the P-gp and MRP2 levels in Caco-2 cell monolayers
(Fig. 3D) in a concentration-dependent manner, although the
e¡ect of DM-L-CyD on P-gp has been already reported [13].
The results of RT-PCR analysis demonstrated that the treat-
ment of apical membranes of Caco-2 cell monolayers with
DM-L-CyD, however, did not change the band densities cor-
responding to MDR1 and MRP2 mRNA (Fig. 3E), indicating
that DM-L-CyD a¡ects a transcription of P-gp and MRP2
only very slightly. Besides, an addition of free cholesterol to
DM-L-CyD-containing bu¡er completely inhibited the release
of P-gp and MRP2 into the apical side’s transport bu¡er (Fig.
3F), suggesting that the ability of inclusion complexation of
DM-L-CyD with cholesterol is involved in the release of the
transporters. These results suggest that the transport activity
of P-gp and MRP2 depends on the amount of cholesterol in
the apical membranes and/or the release of P-gp and MRP2
induced a lowering in the cholesterol content from the apical
membranes of Caco-2 cell monolayers.
3.4. Inhibitory e¡ect of DM-L-CyD on P-gp and MRP2
function refers to caveolae
Caveolae are reported to enrich cholesterol and glycosphin-
golipids [21] and to exist on the plasma membrane of Caco-2
cells and enterocytes [16,22]. We examined the e¡ects of DM-
L-CyD on the localization of cholesterol in Caco-2 cell mono-
layers. Cholesterol was observed in fractions 4^6, consistent
with the localization of caveolin (Fig. 4A), suggesting that
caveolae reside in Caco-2 cell monolayers under the present
experimental conditions. In addition, DM-L-CyD lowered the
cholesterol level in caveolae (Fig. 4A,B). P-gp and MRP2
existed in both low and high density fractions, suggesting
that these proteins resided in both caveolae and non-caveolae
fractions of Caco-2 cell monolayers (Fig. 4C). The treatment
with 10 mM DM-L-CyD for 30 min slightly decreased P-gp
and MRP2 levels in caveolae, but not in non-caveolae (Fig.
4C). In addition, we con¢rmed that the treatment with DM-L-
CyD scarcely a¡ected the caveolin and £otillin-1 levels in
caveolae of Caco-2 cell monolayers. Taken together, these
results suggest that DM-L-CyD is likely to impair P-gp and
MRP2 function through a release of P-gp and MRP2 from
the apical membranes of Caco-2 cell monolayers into the
transport bu¡er.
4. Discussion
We previously reported that DM-L-CyD inhibited P-gp
function in Caco-2 cell monolayers [13]. The present study
demonstrates that DM-L-CyD impaired not only P-gp but
also MRP2 function in Caco-2 cell monolayers, probably
through the release of these transporters from the monolayers,
resulting from the extraction of cholesterol from the caveolae
of the monolayers.
It is noteworthy that DM-L-CyD, and not other CyDs,
signi¢cantly impaired the e¥ux activity of P-gp and MRP2
in the monolayers (Fig. 2). On the other hand, M-L-CyD and
HP-L-CyD, which are widely used as cholesterol-depletion
agents, attenuated the e¥ux activity only very slightly. The
distinction in the inhibitory e¡ect among these CyDs could
be attributed to a di¡erence in inclusion ability, which was
greater for DM-L-CyD than M-L-CyD and HP-L-CyD, e.g.
the solubilizing e¡ect of L-CyDs on cholesterol indeed in-
creased in the order of HP-L-CyD 6M-L-CyD (DS=10.5^
14.7) 6DM-L-CyD (DS=14) (data not shown), probably
resulting from the increase in hydrophobic space of the
CyD cavity [23]. Importantly, these results strongly suggest
that a slight di¡erence in the DS value in methylated L-CyD
may signi¢cantly a¡ects the cellular function with a di¡erent
magnitude.
The inhibitory e¡ect of DM-L-CyD on the e¥ux activity of
P-gp and MRP2 may result from the release of the transport-
ers from the apical membrane of the monolayers into the
apical side’s transport bu¡er via cholesterol depletion in cav-
eolae. This hypothesis may be supported by the results that
L-CyDs changed their message levels only very slightly (Fig.
3E) and DM-L-CyD decreased the levels of P-gp, MRP2 and
cholesterol in caveolae of the monolayers (Fig. 4C). The result
that there was no change in a transcription of MDR1 and
MRP2 may be due to impermeability of L-CyDs through
plasma membranes. The impermeability of L-CyDs can be
adequately explained by the release of P-gp, MRP2 and cho-
lesterol from the monolayers into the apical side’s bu¡er.
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It is well known that CyDs interact with lipids stronger
than proteins [24]. As expected, the activity of DM-L-CyD
to release cholesterol from the Caco-2 cell monolayers was
strongest, followed by M-L-CyD (Fig. 3A). This order was
concomitant with that of the inhibitory e¡ect on the trans-
porter’s function (Fig. 2). In addition, there were good inverse
correlations between cholesterol e¥ux and BL-to-AP trans-
port of rhodamine 123 and BCECF (data not shown) and
an addition of cholesterol to DM-L-CyD-containing bu¡er
provided neither the release of P-gp and MRP2 (Fig. 3F)
nor the impairment of P-gp and MRP2 function (data not
shown) in Caco-2 cell monolayers. Thereby, we presumed
that the inhibitory e¡ect of DM-L-CyD on P-gp and MRP2
function relates to caveolae. As a result, we could con¢rm that
almost all of the cholesterol existed in caveolae and the cho-
lesterol level in caveolae was decreased by the treatment with
DM-L-CyD (Fig. 4A,B). Likewise, the extent of P-gp and
MRP2 in caveolae was decreased by the treatment with
DM-L-CyD (Fig. 4C), although that of caveolin and £otil-
lin-1 was not changed by that with DM-L-CyD. Therefore,
we propose that the ability of DM-L-CyD to release P-gp and
MRP2 from the monolayers can be ascribed to the secondary
e¡ect on the basis of the release of cholesterol from caveolae
of the apical membranes, which may lead to the inhibitory
e¡ect of DM-L-CyD on P-gp and MRP2 function in Caco-2
cell monolayers. However, this selective e¡ect of DM-L-CyD
to release proteins is tempting to speculate the possibility that
DM-L-CyD may release P-gp and MRP2 from non-caveolae
domains of Caco-2 cell monolayers and concomitantly may
allow the transporters to move from caveolar to non-caveolae
domains to replenish them. Elaborate studies are further re-
quired to reveal the mechanism for the e¡ect of DM-L-CyD to
release proteins from apical membranes of Caco-2 cell mono-
layers.
Does cholesterol retaining in the apical membranes of
Caco-2 cell monolayers directly regulate P-gp and MRP2
function? To address the question, we examined the e¡ect
of ¢llipin, caveolae-dispersing agent, on P-gp and MRP2 func-
tion in Caco-2 cell monolayers. As a result, the treatment of
the monolayers with 5 Wg/ml of ¢lipin failed to inhibit BL-to-
AP transport of rhodamine 123 and BCECF in Caco-2 cell
monolayers (data not shown), suggesting that cholesterol does
not regulate P-gp and MRP2 function in a direct manner [25].
However, cholesterol is reported to impart stability to pertur-
bation of bilayer organization by P-gp and moreover this led
to altered protein function in reconstitution system [26]. In
addition, other possibilities in terms of the inhibitory e¡ect
of DM-L-CyD on P-gp and MRP2 function cannot be ruled
out: the change in membrane £uidization [27^29] and P-gp
ATPase activity [30]. Further study regarding the detailed
mechanism for the inhibitory e¡ect of DM-L-CyD on the
transporter’s function should be performed.
In conclusion, of various CyDs, DM-L-CyD markedly im-
paired P-gp and MRP2 function and the inhibitory e¡ect of
DM-L-CyD on the function, at least in part, could be attrib-
uted to the release of these transporters from the apical mem-
branes into the medium in terms of cholesterol-depletion in
caveolae of Caco-2 cell monolayers.
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